Loading
IARC estimates 576 new cancer cases and 349 cancer deaths in Comoros in 2024; the commonest new cancers are cervix uteri, Kaposi sarcoma and oesophagus. This page is assembled automatically from OnCo's data, and says what OnCo does not yet hold.
Built partly from other countries' data. IARC's method code for Comoros's incidence estimate is 5: rates based on incidence estimates or registry data from neighbouring countries. Read the figures as a regional estimate, not a count.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Cervix uteri | 121 | 35.4 | Cervical cancer |
| Kaposi sarcoma | 73 | 9.4 | Kaposi sarcoma |
| Oesophagus | 60 | 9.8 | Oesophageal cancer |
| Prostate | 58 | 22.0 | Prostate cancer |
| Breast | 50 | 15.0 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Liver and intrahepatic bile ducts | 35 | 5.3 | Hepatocellular carcinoma |
| Bladder | 18 | 3.0 | Bladder & urothelial cancer |
| Non-Hodgkin lymphoma | 18 | 2.4 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Colorectum | 16 | 2.9 | Colorectal cancer |
| Stomach | 13 | 2.2 | Gastric & gastro-oesophageal junction cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Cervix uteri | 70 | 21.0 | Cervical cancer |
| Oesophagus | 56 | 9.3 | Oesophageal cancer |
| Prostate | 35 | 13.6 | Prostate cancer |
| Liver and intrahepatic bile ducts | 35 | 5.3 | Hepatocellular carcinoma |
| Kaposi sarcoma | 24 | 3.1 | Kaposi sarcoma |
| Breast | 23 | 7.1 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 15 | 2.8 | Colorectal cancer |
| Bladder | 13 | 2.2 | Bladder & urothelial cancer |
| Stomach | 12 | 2.1 | Gastric & gastro-oesophageal junction cancer |
| Trachea, bronchus and lung | 7 | 1.2 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
No trial record in OnCo lists a site in Comoros. OnCo reads sites from ClinicalTrials.gov; studies registered only elsewhere are searchable through the WHO International Clinical Trials Registry Platform.
OnCo holds no institution, company or person in Comoros.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Comoros is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
Comoros is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.